RE:RE:True to form"Aezs down from close out on Friday at $13 and still free falling..."
AEZS has essentially been trading around C$11 for almost three months with the exception of a brief spike into the closing of the deal as some captured the warrants. With the AEZS warrants no longer available the stock has fallen back to around $11 where it was.
"PGX nowhere near complete..."
PGX was commissioned in Q1 as expected and has been going through its fine tuning phase. They run a number of trials until perfected. ONly an idiot would think there would be no fine tuning given the number of variables. PGX is on schedule and PGX could have its first approved product by the end of the year. The 100L scale-up is also on schedule and expected to be commissioned in Q3 which isn't far now.
"Aezs into the ground with only a 1.5 year of cash available before they go brankrupt..."
You have no idea how much cash is availlable in the next 1.5 years. They have about C$40 million cash. They are delisting from the TSX-V saving costs. Together they only need one President, CEO, and IR function and they are in the process of consolidating and streamlining the two companies more generally to save costs. AEZS's diagnostic clinical trial is complete meaning no more cash burn for this clinical trial. If approved it turns into a cashcow. The previous licensee paid C$40 million upfront adjusted for inflation for a license plus milestones and royalties. AEZS can license the diagnostic again but this time for the target pediatric market and potentially as the industry's first standalone test. With the approval of PGX's first product by the end of the year this can bring in revenue. There's also the chewy product and the malted avenanthramide for food applications, and the powder formulation of beta glucan being evaluated with Symrise. With PGX expected to reach the decision point for mass industrialization this year it can be licensed or upfront money, milestones and royalties. Witht eh added resources of AEZS they are in a stronger position than ever for a deal. The wound healing program can also be licensed with the new data. AEZS has a pipeline that can be licensed. The new company will also do an overview of their projects and focus on the best risk-reward potentially cutting some projects to save costs. The avenanthramide pill can also potentially be licensed for upfront cash, milestone payment, and royalties once the current Phase I/IIa trial is complete providing safety/tolerability and preliminary efficacy data in humans. The plan previously has been to license at this stage.
The AGM next month should provide a good overview of their plans moving forward now that they are in the drivers seat.
Transformational products...
"Ronald W. Miller, Chair of the Company. “With the successful completion of this merger, we are now optimized to bring value-driving, transformational products to the market.”" news release